Small-molecule PSMA ligands. Current state, SAR and perspectives
- 10 March 2016
- journal article
- other
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 24 (8) , 679-693
Abstract
Prostate cancer (PC) is the prevalent malignancy widespread among men in the Western World. Prostate specific membrane antigen (PSMA) is an established PC marker and has been considered as a promising biological target for anti-PC drug delivery and diagnostics. The protein was found to be overexpressed in PC cells, including metastatic, and the neovasculature of solid tumors. These properties make PSMA-based approach quite appropriate for effective PC imaging and specific drug therapy. Through the past decade, a variety of PSMA-targeted agents has been systematically evaluated. Small molecule compounds have several advantages over other classes, such as improved pharmacokinetics and rapid blood clearance. These low-weight ligands have similar structure and can be divided into three basic categories in accordance with the type of their zinc-binding core-head. Several PSMA binders are currently undergoing clinical trials generally for PC imaging. The main goal of the present review is to describe the recent progress achieved within the title field and structure activity relationships (SAR) disclosed for different PSMA ligands. Recent in vitro and in vivo studies for each type of the compounds described have also been briefly summarized.Keywords
This publication has 63 references indexed in Scilit:
- Targeted Inhibition of Prostate Cancer Metastases with an RNA Aptamer to Prostate-specific Membrane AntigenMolecular Therapy, 2014
- Cancer statistics, 2014CA: A Cancer Journal for Clinicians, 2014
- Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2013
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Preclinical Evaluation of Novel Glutamate-Urea-Lysine Analogues That Target Prostate-Specific Membrane Antigen as Molecular Imaging Pharmaceuticals for Prostate CancerCancer Research, 2009
- Androgen Deprivation Therapy for Prostate CancerJAMA, 2005
- Epithelial stem cells in human prostate growth and diseaseProstate Cancer and Prostatic Diseases, 2004
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003
- Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patientsInternational Journal of Cancer, 2003
- Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastasesUrology, 1998